Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets

Pei Chen Yu, Chen Hao Huang, Chih Jung Kuo, Po Huang Liang, Lily Hui Ching Wang, Max Yu Chen Pan, Sui Yuan Chang, Tai Ling Chao, Si Man Ieong, Jun Tung Fang, Hsuan Cheng Huang*, Hsueh Fen Juan

*此作品的通信作者

研究成果: Article同行評審

2 引文 斯高帕斯(Scopus)

摘要

Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been rapidly spreading worldwide, causing hundreds of millions of infections. Despite the development of vaccines, insufficient protection remains a concern. Therefore, the screening of drugs for the treatment of coronavirus disease 2019 (COVID-19) is reasonable and necessary. This study utilized bioinformatics for the selection of compounds approved by the U.S. Food and Drug Administration with therapeutic potential in this setting. In addition, the inhibitory effect of these compounds on the enzyme activity of transmembrane protease serine 2 (TMPRSS2), papain-like protease (PLpro), and 3C-like protease (3CLpro) was evaluated. Furthermore, the capability of compounds to attach to the spike-receptor-binding domain (RBD) was considered an important factor in the present assessment. Finally, the antiviral potency of compounds was validated using a plaque reduction assay. Our funnel strategy revealed that tamoxifen possesses an anti-SARS-CoV-2 property owing to its inhibitory performance in multiple assays. The proposed time-saving and feasible strategy may accelerate drug screening for COVID-19 and other diseases.

原文English
文章編號176
期刊Pharmaceutics
14
發行號1
DOIs
出版狀態Published - 1月 2022

指紋

深入研究「Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets」主題。共同形成了獨特的指紋。

引用此